Unexpectedly, shRNA-mediated FAM83A knockdown in HER2+ BC appears to primarily inhibit signaling through the PI3K/Akt pathway compared to TNBCs, where FAM83A knockdown decreases both PI3K/Akt and MAPK signaling [32, 33]. The gene discussed is ERBB2; the disease is breast cancer.